Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 41^st Annual J.P. Morgan Healthcare Conference scheduled for January 11th at 2:15 PM PT. The management team's presentation will be available for 30 days via a live audio webcast on the company's website.

Inari focuses on medical devices aimed at treating venous diseases. Their products include the ClotTriever and FlowTriever systems, both 510(k)-cleared by the FDA, designed for non-surgical removal of clots in patients with conditions like deep vein thrombosis and pulmonary embolism.

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 2:15PM Pacific Time.

A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

When is Inari Medical's presentation at the J.P. Morgan Healthcare Conference?

Inari Medical will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11th at 2:15 PM Pacific Time.

How can I access the Inari Medical presentation from the conference?

The presentation will be available for 30 days via a live audio webcast on Inari Medical's website in the Investor Relations section.

What medical devices does Inari Medical offer?

Inari Medical offers the ClotTriever and FlowTriever systems, both designed for the non-surgical removal of clots from large blood vessels.

Is Inari Medical's ClotTriever system FDA cleared?

Yes, the ClotTriever system is 510(k)-cleared by the FDA for the non-surgical removal of clots from peripheral blood vessels.

What conditions do Inari Medical's devices target?

Inari Medical's devices target venous thromboembolism, specifically deep vein thrombosis and pulmonary embolism.